IceCure Medical Gets China Patent Allowance for Cryoablation Pump

Ticker: ICCM · Form: 6-K · Filed: Mar 17, 2025 · CIK: 1584371

Sentiment: bullish

Topics: patent, intellectual-property, medical-devices, china

TL;DR

China patent allowance for IceCure's new cryo pump - big win for IP protection!

AI Summary

On March 17, 2025, IceCure Medical Ltd. announced it received a Notice of Allowance in China for its novel cryogenic pump, a key component for its next-generation cryoablation technology. This allowance is a significant step towards protecting their intellectual property in a major market.

Why It Matters

This patent allowance in China could protect IceCure's innovative cryoablation technology in a large market, potentially boosting future sales and market share.

Risk Assessment

Risk Level: low — The filing is an announcement of a patent allowance, which is generally positive news with low immediate risk.

Key Players & Entities

FAQ

What specific technology does the Notice of Allowance in China pertain to?

The Notice of Allowance in China pertains to IceCure Medical Ltd.'s novel cryogenic pump, which is a key component for their next-generation cryoablation technology.

When was this Notice of Allowance announced by IceCure Medical Ltd.?

The Notice of Allowance was announced on March 17, 2025, via a press release.

What is the significance of this Notice of Allowance for IceCure Medical Ltd.?

The significance lies in the protection of their intellectual property for their novel cryogenic pump in the Chinese market, which is crucial for their next-generation cryoablation technology.

What form is this SEC filing?

This SEC filing is a Form 6-K, which is a Report of Foreign Private Issuer.

Where is IceCure Medical Ltd. headquartered?

IceCure Medical Ltd. is headquartered in Caesarea, Israel.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on March 17, 2025 regarding IceCure Medical Ltd. (ICCM).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing